文献速递血液净化与透析慢性肾脏病

可溶性尿激酶纤溶酶原激活物受体与血液透析糖尿病患者结局

Soluble Urokinase Plasminogen Activator Receptor and Outcomes in Patients with Diabetes on Hemodialysis.
PubMed 文献 · Clin J Am Soc Nephrol · 2017-05-11

在1175例接受血液透析的2型糖尿病患者中,中位随访4年,血浆可溶性尿激酶纤溶酶原激活物受体(suPAR)水平与全因死亡、心血管事件及感染相关死亡相关。suPAR第三分位(>11633 pg/ml)患者较第一分位(<9599 pg/ml)全因死亡风险增加60%,心血管事件风险增加48%。

要点

  • 血透糖尿病患者中,suPAR>11633 pg/ml与全因死亡风险增加60%独立相关。
  • suPAR升高与心血管事件风险增加48%相关,突发死亡和卒中风险亦升高。
  • suPAR对全因死亡和心血管事件的风险判别能力提升有限(ΔC统计量0.02)。

核心结论

  • 在血液透析的2型糖尿病患者中,suPAR水平与全因死亡、心血管事件及感染相关死亡的相关性持续存在。

研究设计与样本

  • 德国糖尿病与透析研究(German Diabetes and Dialysis Study)纳入1175例接受血液透析的2型糖尿病患者,平均年龄66±8岁,54%为男性,中位随访4年。

主要发现

  • suPAR中位水平为10521 pg/ml(四分位距9105-12543 pg/ml)。
  • suPAR第三分位(>11633 pg/ml)较第一分位(<9599 pg/ml)全因死亡风险增加60%(HR 1.60;95%CI 1.27-2.03)。
  • suPAR第三分位与突发死亡风险增加98%(HR 1.98;95%CI 1.27-3.09)和卒中风险增加74%(HR 1.74;95%CI 1.05-2.90)相关。
  • suPAR第三分位与心血管事件风险增加48%相关(HR 1.48;95%CI 1.15-1.89)。
  • 调整C反应蛋白、白细胞计数和非对称二甲基精氨酸后,上述关联持续存在。

关键数值与推荐

  • suPAR对全因死亡的风险判别改善ΔC统计量为0.02(95%CI 0.00-0.03)。
  • suPAR对心血管事件的风险判别改善ΔC统计量为0.02(95%CI 0.00-0.05)。

临床怎么用

  • 在血液透析的2型糖尿病患者中,检测血浆suPAR水平可能有助于识别全因死亡和心血管事件高风险患者。
  • suPAR对风险判别的改善幅度较小,尚不足以单独作为临床决策工具。

局限性

  • suPAR与结局关联的潜在通路尚不明确,需进一步研究。
  • suPAR对风险判别的改善幅度有限(ΔC统计量0.02)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Soluble urokinase plasminogen activator receptor is a novel biomarker strongly predictive of cardiovascular outcomes implicated in the pathogenesis of kidney disease. Soluble urokinase plasminogen activator receptor levels, however, correlate with declining kidney function. It is unclear whether soluble urokinase plasminogen activator receptor levels remain associated with outcomes in patients with ESRD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We measured plasma soluble urokinase plasminogen activator receptor levels in 1175 patients (mean age =66±8 years old, 54% men) with type 2 diabetes mellitus on hemodialysis participating in the German Diabetes and Dialysis Study followed for a median of 4 years for outcomes including all-cause death, cardiovascular events, and infection-related mortality. Survival analysis was performed using stepwise Cox proportional hazards models adjusted for potential confounders. Also, adjustments were made for inflammatory markers (C-reactive protein and leukocyte count) and the oxidative stress marker asymmetric dimethyl arginine to investigate potential mediators of the relationship between soluble urokinase plasminogen activator receptor and outcomes. RESULTS: Median soluble urokinase plasminogen activator receptor levels were 10,521 pg/ml (interquartile range, 9105-12,543 pg/ml). When stratified by tertiles, patients with soluble urokinase plasminogen activator receptor >11,633 pg/ml (third tertile) had adjusted 1.6-fold higher mortality (hazard ratio, 1.60; 95% confidence interval, 1.27 to 2.03) compared with those with low soluble urokinase plasminogen activator receptor <9599 pg/ml (first tertile). Risks of sudden death and stroke were higher (adjusted hazard ratio, 1.98; 95% confidence interval, 1.27 to 3.09 and adjusted hazard ratio, 1.74; 95% confidence interval, 1.05 to 2.90, respectively), together accounting for higher incidence of cardiovascular events (adjusted hazard ratio, 1.48; 95% confidence interval, 1.15 to 1.89). Associations with outcomes persisted after adjusting for C-reactive protein, leukocyte count, and asymmetric dimethyl arginine. Addition of soluble urokinase plasminogen activator receptor to a risk factor model modestly improved risk discrimination for all-cause death (ΔC statistic, 0.02; 95% confidence interval, 0.00 to 0.03) and cardiovascular events (ΔC statistic, 0.02; 95% confidence interval, 0.00 to 0.05). CONCLUSIONS: The association of soluble urokinase plasminogen activator receptor levels with outcomes persists in patients on hemodialysis. Additional study is warranted to characterize the underlying pathways of that association, which may yield opportunities to develop new therapeutic strategies.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Drechsler C, Hayek SS, Wei C, et al. Soluble Urokinase Plasminogen Activator Receptor and Outcomes in Patients with Diabetes on Hemodialysis. Clin J Am Soc Nephrol. 2017. PMID: 28495863. doi:10.2215/CJN.10881016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。